<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="365876">
  <stage>Registered</stage>
  <submitdate>27/02/2014</submitdate>
  <approvaldate>7/03/2014</approvaldate>
  <actrnumber>ACTRN12614000248662</actrnumber>
  <trial_identification>
    <studytitle>Cannabidiol (CBD) for the Management of Cannabis Withdrawal: A Phase II Proof of Concept Study</studytitle>
    <scientifictitle>Cannabidiol (CBD) for the Management of Cannabis Withdrawal: A Phase II Proof of Concept Study</scientifictitle>
    <utrn>U1111-1153-9442 </utrn>
    <trialacronym>CBD study</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cannabis Withdrawal</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Research that is not of generic health relevance and not applicable to specific health categories listed above</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Addiction</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Single subject repeated measures design of an open label administration of Cannabidiol to 5 subjects withdrawing from cannabis use in an inpatient setting. 300mg of CBD will be administered once on day 1, twice bd on days 2-5 and once on day 6. participants will be discharged on day 7. CBD will be administered orally in capsules.</interventions>
    <comparator>N/a</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Reduction of number and severity of withdrawal symptoms including-Insomnia, anxiety, agitation, restlessness, low mood.The Cannabis Withdrawal Cale will be used to monitor symptoms.</outcome>
      <timepoint>Day 7 discharge. Patients will be monitored for number of symptoms and withdrawal severity each day using the Cannabis Withdrawal scale. Patients will undergo Urine and blood testing on day 1, day 4 and day 7, then again on day 28.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Retention in treatment
Abstinence at 28 day followup</outcome>
      <timepoint>Day 7 post admission and again at day 28 post admission.
</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Cannabis dependency
Adult
</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Poly substance dependence, Co-morbid Mental Health Diagnosis, Intellectual disability, Substance abuse treatment in previous 30 days, Evidence of severe medical condition (cardiac, renal, hepatic), Pregnant women or those wishing to start a family imminently, not willing to abide by NSW Health rules for inpatient admission.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>Open label study with participants recruited on a first in first served basis once inclusion and exclusion criteria have been met.</concealment>
    <sequence>n/a</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures>Small n=5 phase II proof of concept study</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods>There is not statistical assumptions needed for this type of study as it is a single subject n=1 design where the procedure is repeated 4 more times to verify any changes in the initial subject. This is a well known and validated experimental design.</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>21/03/2014</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>5</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Nepean Hospital - Kingswood</hospital>
    <postcode>2747 - Kingswood</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>UNSW</primarysponsorname>
    <primarysponsoraddress>22-32 King Street
Randwick  NSW  2031</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>University of NSW(UNSW) -National Cannabis Prevention and Information Centre (NCPIC) core funds</fundingname>
      <fundingaddress>22-32 King Street, Randwick, NSW, 2031</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>n/a</sponsorname>
      <sponsoraddress>n/a</sponsoraddress>
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Hospital</othercollaboratortype>
      <othercollaboratorname>Cumberland Hospital</othercollaboratorname>
      <othercollaboratoraddress>Building 83, 1-11 Hainsowrth Street, Westmead, NSW 2145
</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Hospital</othercollaboratortype>
      <othercollaboratorname>Nepean Hospital</othercollaboratorname>
      <othercollaboratoraddress>Somerset Street, Kingswood, NSW, 2747</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The aim of the study is to examine the safety and efficacy of cannabidiol (CBD) in the inpatient management of cannabis withdrawal in an open label study. Specifically the study will assess the impact of CBD on the number and severity of withdrawal symptoms, detoxification completion and adverse events in n=5, using an intention to treat analysis.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Western Sydney Local Health District</ethicname>
      <ethicaddress>Western Sydney Local Health District Office, Westmead Hospital Campus, Institute Road, Westmead NSW 2145</ethicaddress>
      <ethicapprovaldate>28/10/2013</ethicapprovaldate>
      <hrec>HREC2013/9/4.6 (3774) AU RED HREC/13/WMEAD/229</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Jan Copeland</name>
      <address>NCPIC-UNSW
22-32 King Street
Randwick,  NSW,  2031</address>
      <phone>+61 2 93850231</phone>
      <fax>+61 293850201</fax>
      <email>j.copeland@unsw.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Nicole Clement</name>
      <address>NCPIC-UNSW
22-32 King Street
Randwick,  NSW,  2031</address>
      <phone>+61 417651223</phone>
      <fax>+61 293850201</fax>
      <email>n.clement@unsw.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Jan Copeland</name>
      <address>NCPIC-UNSW
22-32 King Street
Randwick,  NSW,  2031</address>
      <phone>+61 293850231</phone>
      <fax>+61 293850201</fax>
      <email>j.copeland@unsw.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Nicole Clement</name>
      <address>NCPIC-UNSW
22-32 King Street
Randwick,  NSW,  2031</address>
      <phone>+61 417651223</phone>
      <fax>0293850201</fax>
      <email>n.clement@unsw.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>